Core Insights - The company is experiencing growth driven by significant funding from the "One Big Beautiful Bill," particularly for non-intrusive inspection (NII) scanning equipment, with an allocation of approximately $1.0 billion to $1.1 billion [1] - Management anticipates incremental growth to be more U.S.-focused, with substantial orders expected for border deployments and opportunities tied to the "Golden Dome" initiative [2] - Recent security growth has been heavily influenced by international contracts, especially in Mexico, where the company secured contracts worth about $900 million with the Mexican Army and Navy [3] Business Segments - The company operates three primary divisions: Security, Optoelectronics, and Healthcare, with Security being the largest, accounting for over two-thirds of revenue and profit [7] - The Healthcare segment, which constitutes less than 10% of revenue, focuses on patient monitoring and cardiology equipment, with about half of its revenue being recurring [4] - Optoelectronics represents about a quarter of revenue, producing sensors and electronic components for various markets, supporting margin and supply chain control through vertical integration [5] Growth Drivers - The company has historically won about 40% to 45% of overall awards from U.S. Customs and Border Protection (CBP) and is well-positioned for future awards, with limited competition in cargo inspection [8] - The "Golden Dome" initiative is linked to RF technology from a recent acquisition, and the company is expanding manufacturing capacity in Texas to support anticipated growth [9] - Management expects a shift towards service revenue in the Security division, which currently accounts for about 30% of divisional revenue, with plans to increase this significantly [13] Financial Outlook - The company sees an "inflection point" for free cash flow through calendar 2026 and into 2027, driven by profits and working capital release [14] - Cash generation is expected to normalize as contracts in Mexico wind down, with capital allocation priorities including M&A, share repurchases, and debt reduction [14] - The Healthcare division is undergoing operational changes aimed at increasing R&D investment, which could lead to meaningful growth despite its smaller size [15]